(Reuters) – Eli Lilly and Co said on Wednesday it had submitted a request to the U.S. Food and Drug Administration for emergency use of its experimental antibody treatment for COVID-19.
Separately, the U.S. drugmaker said data from a new study showed a combination of two of its antibody treatments helped reduce hospitalization and emergency room visits for COVID-19 patients.
(Reporting by Manas Mishra in Bengaluru; Editing by Ramakrishnan M.)
